Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Ouattara, Amed ^a,b,c   Mu, Jianbing ^b   Takala Harrison, Shannon ^c   Saye, Renion ^a   Sagara, Issaka ^a   Dicko, Alassane ^a   Niangaly, Amadou ^a   Duan, Junhui ^b   Ellis, Ruth D ^b   Miller, Louis H ^b   Su, Xin Zhuan ^b   Plowe, Christopher V ^c   Doumbo, Ogobara K ^a  

^a UNIVERSITY OF BAMAKO   (Mali)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; APICAL MEMBRANE ANTIGEN 1; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MALARIA VACCINE; RECOMBINANT ANTIGEN; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; MEMBRANE PROTEIN; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ALLELE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GENE CLUSTER; GENE SEQUENCE; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; IMMUNIZATION; INFECTION RISK; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PROTECTION; PROTEIN DOMAIN; SEQUENCE ANALYSIS; AMINO ACID SEQUENCE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GENETICS; IMMUNOLOGY; PARASITOLOGY; POLYMERASE CHAIN REACTION;

ALLELES; ALUMINUM HYDROXIDE; AMINO ACID SEQUENCE; ANTIGENS, PROTOZOAN; CHILD; DOUBLE-BLIND METHOD; HAPLOTYPES; HUMANS; IMMUNIZATION; MALARIA VACCINES; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS;

EID: 77953673075     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-175     Document Type: Article

References (42)

1. World Malaria Report, 2008. WHO, http://www.who.int/malaria/wmr2008/ malaria2008.pdf
2. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. CV Plowe P Alonso SL Hoffman, J Infect Dis 2009 200 1639 1643 10.1086/646613 19877843
3. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. B Genton I Betuela I Felger F Al-Yaman RF Anders A Saul L Rare M Baisor K Lorry GV Brown D Pye DO Irving TA Smith HP Beck MP Alpers, J Infect Dis 2002 185 820 827 10.1086/339342 11920300
4. Vaccines against malaria - an update. K Matuschewski AK Mueller, FEBS Journal 2007 274 4680 4687 10.1111/j.1742-4658.2007.05998.x 17824954
5. Protective efficacy of the RTS, S/ASO2 Plasmodium falciparum malaria vaccine is not strain specific. A Alloueche P Milligan DJ Conway M Minder K Bojang T Doherty N Tornieporth J Cohen BM Greenwood, Am J Trop Med Hyg 2003 68 97 101 12556156
6. RTS, S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. S Enosse C Doban D Quelhas JJ Aponte M Lievens A Leach J Sacarlal B Greenwood J Milman F Dubovsky J Cohen R Thompson WR Ballou PL Alonso DJ Conway CJ Sutherland, PLoS Clin Trials 2006 1 5 10.1371/journal.pctr.0010005 16871327
7. Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. CH Kocken AM van der Wel MA Dubbeld DL Narum FM van de Rijke GJ Van Gemert X van dL LH Bannister C Janse AP Waters AW Thomas, J Biol Chem 1998 273 15119 15124 10.1074/jbc.273.24.15119 9614123
8. Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. JA Deans T Alderson AW Thomas GH Mitchell ES Lennox S Cohen, Clin Exp Immunol 1982 49 297 309 6751636
9. The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes. AW Thomas JA Deans GH Mitchell T Alderson S Cohen, Mol Biochem Parasitol 1984 13 187 199 10.1016/0166-6851(84)90112-9 6513992
10. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen-1 and induction of antibodies that inhibit erythrocyte invasion. CH Kocken C Withers-Martinez MA Dubbeld WA van der F Hackett A Valderrama MJ Blackman AW Thomas, Infect Immun 2002 70 4471 4476 10.1128/IAI.70.8.4471-4476.2002 12117958
11. Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen-1 of Plasmodium falciparum merozoites. S Dutta JD Haynes JK Moch A Barbosa DE Lanar, Proc Natl Acad Sci USA 2003 100 12295 12300 10.1073/pnas.2032858100 14526103
12. High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. AW Thomas JF Trape C Rogier A Goncalves VE Rosario DL Narum, Am J Trop Med Hyg 1994 51 730 740 7810805
13. Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII. V Udhayakumar S Kariuki M Kolczack M Girma JM Roberts AJ Oloo BL Nahlen AA Lal, Am J Trop Med Hyg 2001 65 100 107 11508382
14. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Anders F Robin Crewther E Pauline Edwards Stirling Margetts Mai Matthew LSM Mary Pollock Bronwyn Pye David, Vaccine 1998 16 240 247 10.1016/S0264-410X(97)88331-4 9607037
15. Structure of domain III of the blood stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1. M Nair MG Hinds AM Coley AN Hodder M Foley RF Anders RS Norton, J Mol Biol 2002 322 741 753 10.1016/S0022-2836(02)00806-9 12270711
16. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: Implications for vaccine development. SL Takala D Coulibaly MA Thera AH Batchelor MP Cummings AA Escalante A Ouattara K Traoré A Niangaly A Djimdé OK Doumbo CV Plowe, Sci Transl Med 2009 1 2ra5 20165550
17. Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. T Bai M Becker A Gupta P Strike VJ Murphy RF Anders AH Batchelor, Proc Natl Acad Sci USA 2005 102 12736 12741 10.1073/pnas.0501808102 16129835
18. Invasion of red blood cells by malaria parasites. AF Cowman BS Crabb, Cell 2006 124 755 766 10.1016/j.cell.2006.02.006 16497586
19. Structural basis of antigenic escape of a malaria vaccine candidate. S Dutta SY Lee AH Batchelor DE Lanar, Proc Natl Acad Sci USA 2007 104 12488 93 10.1073/pnas.0701464104 17636123
20. Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. A Dicko I Sagara RD Ellis K Miura O Guindo B Kamate M Sogoba MB Niambele M Sissoko M Baby A Dolo GED Mullen MP Fay M Pierce DA Diallo A Saul LH Miller OK Doumbo, PLoS ONE 2008 3 1563 10.1371/journal.pone.0001563 18270560
21. Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians. A Dicko DJ Diemert I Sagara M Sogoba MB Niambele MH Assadou O Guindo B Kamate M Baby M Sissoko ME Malkin MP Fay MA Thera K Miura A Dolo DA Diallo GE Mullen CA Long A Saul O Doumbo LH Miller, PLoS ONE 2007 2 1045 10.1371/journal.pone.0001045 17940609
22. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. A Cortés M Mellombo I Mueller A Benet JC Reeder FA Anders, Infect Immun 2003 71 1416 1426 10.1128/IAI.71.3.1416-1426.2003 12595459
23. Apical membrane antigen 1: a malaria vaccine candidate in review. EJ Remarque BW Faber CHM Kocken AW Thomas, Trends Parasitol 2007 24 74 84 10.1016/j.pt.2007.12.002
24. The global distribution of clinical episodes of Plasmodium falciparum malaria. RW Snow CA Guerra MA Noor HY Myint SI Hay, Nature 2005 434 214 217 10.1038/nature03342 15759000
25. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. PE Crewther ML Matthew RH Flegg RF Anders, Infect Immun 1996 64 3310 3317 8757869
26. Specificity of the Protective Antibody Response to apical membrane antigen 1. AN Hodder PE Crewther RF Anders, Infect Immun 2001 69 3286 3294 10.1128/IAI.69.5.3286-3294.2001 11292751
27. Mixed allele malaria vaccines: Host protection and within-host selection. VC Barclay H.K Brian BHK Chan RF Anders AF Read, Vaccine 2008 26 6099 6107 10.1016/j.vaccine.2008.09.004 18804509
28. Genetic diversity and malaria vaccine design, testing, and efficacy: Preventing and overcoming "vaccine resistant malaria. S-L Takala CV Plowe, Parasite Immunol 2009 31 560 573 10.1111/j.1365-3024.2009.01138.x 19691559
29. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. I Sagara A Dicko RD Ellis MP Fay SI Diawara MH Assadou MS Sissoko M Kone AI Diallo R Saye MA Guindo O Kante MB Niambele K Miura GE Mullen M Pierce LB Martin A Dolo DA Diallo OK Doumbo LH Miller A Saul, Vaccine 2009 27 3090 3098 10.1016/j.vaccine.2009.03.014 19428923
30. Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: Implications for vaccine design. J Duan J Mu MA Thera D Joy SLK Pond D Diemert C Long H Zhou K Miura A Ouattara A Dolo O Doumbo X Su L Miller, Proc Natl Acad Sci USA 2008 105 7857 7862 10.1073/pnas.0802328105 18515425
31. Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. K Tamura J Dudley M Nei S Kumar, Mol Biol Evol 2007 24 1596 1599 10.1093/molbev/msm092 17488738
32. DNASP, DNA polymorphism analyses by a coalescent and other methods. J Rozas JC Sanchez-Delbarrrio X Messeguer R Rozas, Bioinformatics 2003 19 2496 2497 10.1093/bioinformatics/btg359 14668244
33. Inference of population structure using multilocus genotype data: Linked loci and correlated allele frequencies. D Falush M Stephens JK Pritchard, Genetics 2003 164 1567 1587 12930761
34. Ogobara Doumbo Ok: Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali. A Dicko C Mantel B Kouriba I Sagara MA Thera S Doumbia M Diallo B Poudiougou Diakite, Trop Med Int Health 2005 10 550 556 10.1111/j.1365-3156.2005.01418.x 15941418
35. Asexual blood-stage malaria vaccine development: facing the challenges. B Genton ZH Reed, Curr Opin Infect Dis 2007 20 467 475 10.1097/QCO. 0b013e3282dd7a29 17762779
36. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. AW Stowers MC Kennedy BP Keegan A Saul CA Long LH Miller, Infect Immun 2002 70 6961 6967 10.1128/IAI.70.12.6961-6967.2002 12438375
37. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. MC Kennedy J Wang Y Zhang AP Miles F Chitsaz A Saul CA Long LH Miller AW Stowers, Infect Immun 2002 70 6948 6960 10.1128/IAI.70.12. 6948-6960.2002 12438374
38. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. RD Ellis GE Mullen M Pierce LB Martin K Miura MP Fay CA Long D Shaffer A Saul LH Miller AP Durbin, Vaccine 2009 27 4104 4109 10.1016/j.vaccine.2009.04.077 19410624
39. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. I Sagara RD Ellis A Dicko MB Niambele B Kamate O Guindo MS Sissoko MP Fay MA Guindo O Kante R Saye K Miura C Long GE Mullen M Pierce LB Martin K Rausch A Dolo DA Diallo LH Miller OK Doumbo, Vaccine 2009 27 7292 7298 10.1016/j.vaccine.2009.10.087 19874925
40. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. GE Mullen RD Ellis K Miura E Malkin C Nolan M Hay MP Fay A Saul D Zhu K Rausch S Moretz H Zhou CA Long LH Miller J Treanor, PLoS ONE 2008 3 2940 10.1371/journal.pone.0002940 18698359
41. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. MA Thera OK Doumbo D Coulibaly DA Diallo AK Kone AB Guindo K Traore A Dicko I Sagara MS Sissoko M Baby M Sissoko I Diarra A Niangaly A Dolo M Daou SI Diawara DG Heppner VA Stewart E Angov ES Bergmann-Leitner DE Lanar S Dutta L Soisson CL Diggs A Leach A Owusu MC Dubois J Cohen JN Nixon A Gregson SL Takala KE Lyke CV Plowe, PLoS ONE 2008 3 1465 10.1371/journal.pone.0001465 18213374
42. Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial. MA Thera OK Doumbo D Coulibaly MB Laurens KA Kone AB Guindo K Traore M Sissoko DA Diallo Diarra Issa B Kouriba M Daou A Dolo M Baby MS Sissoko A Sagara A Niangaly I Traore A Olotu O Godeaux A Leach MCW Dubois R Ballou J Cohen D Thompson T Dube L Soisson CL Diggs SL Takala KE Lyke B House DE Lanar S Dutta DG Heppner CV Plowe, PLoS ONE 2010 5 9041 10.1371/journal.pone.0009041 20140214